» Articles » PMID: 29123033

Inactivation of the MDM2 RING Domain Enhances P53 Transcriptional Activity in Mice

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2017 Nov 11
PMID 29123033
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The MDM2 RING domain harbors E3 ubiquitin ligase activity critical for regulating the degradation of tumor suppressor p53, which controls many cellular pathways. The MDM2 RING domain also is required for an interaction with MDMX. Mice containing a substitution in the MDM2 RING domain, MDM2, disrupting MDM2 E3 function and the MDMX interaction, die during early embryogenesis that can be rescued by p53 deletion. To investigate whether MDM2, which retains p53 binding, has p53-suppressing activity, we generated ; mice, in which we replaced the endogenous alleles with an inducible allele, and compared survival with that of similarly generated ; mice. Adult -null mice died ∼7 days after tamoxifen-induced p53 activation, indicating that in the absence of MDM2, MDMX cannot suppress p53. Surprisingly, ; mice died ∼5 days after tamoxifen injection, suggesting that p53 activity is higher in the presence of MDM2 than in the absence of MDM2. Indeed, in MDM2-expressing mouse tissues and embryonic fibroblasts, p53 exhibited higher transcriptional activity than in those expressing no MDM2 or no MDM2 and MDMX. This observation indicated that MDM2 not only is unable to suppress p53 but may have gained the ability to enhance p53 activity. We also found that p53 acetylation, a measure of p53 transcriptional activity, was higher in the presence of MDM2 than in the absence of MDM2. These results reveal an unexpected role of MDM2 in enhancing p53 activity and suggest the possibility that compounds targeting MDM2 RING domain function could produce even more robust p53 activation.

Citing Articles

FGF12 Positively Regulates Keratinocyte Proliferation by Stabilizing MDM2 and Inhibiting p53 Activity in Psoriasis.

Wang N, Xu X, Guan F, Lin Y, Ye Y, Zhou J Adv Sci (Weinh). 2024; 11(39):e2400107.

PMID: 39234815 PMC: 11497104. DOI: 10.1002/advs.202400107.


Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.

Traweek R, Cope B, Roland C, Keung E, Nassif E, Erstad D Front Oncol. 2022; 12:1006959.

PMID: 36439412 PMC: 9684653. DOI: 10.3389/fonc.2022.1006959.


Inhibition of the lncRNA prevents podocyte injury and mitotic catastrophe in diabetic nephropathy.

Wang Z, Chang Y, Liu Y, Liu B, Zhen J, Li X Mol Ther Nucleic Acids. 2022; 28:136-153.

PMID: 35402074 PMC: 8956887. DOI: 10.1016/j.omtn.2022.03.001.


Regulating tumor suppressor genes: post-translational modifications.

Chen L, Liu S, Tao Y Signal Transduct Target Ther. 2020; 5(1):90.

PMID: 32532965 PMC: 7293209. DOI: 10.1038/s41392-020-0196-9.


How to Inactivate Human Ubiquitin E3 Ligases by Mutation.

Garcia-Barcena C, Osinalde N, Ramirez J, Mayor U Front Cell Dev Biol. 2020; 8:39.

PMID: 32117970 PMC: 7010608. DOI: 10.3389/fcell.2020.00039.


References
1.
Jones S, Roe A, Donehower L, Bradley A . Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995; 378(6553):206-8. DOI: 10.1038/378206a0. View

2.
Wang X, Taplick J, Geva N, Oren M . Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 2004; 561(1-3):195-201. DOI: 10.1016/S0014-5793(04)00168-1. View

3.
Wade M, Wang Y, Wahl G . The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010; 20(5):299-309. PMC: 2910097. DOI: 10.1016/j.tcb.2010.01.009. View

4.
Ito A, Lai C, Zhao X, Saito S, Hamilton M, Appella E . p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001; 20(6):1331-40. PMC: 145533. DOI: 10.1093/emboj/20.6.1331. View

5.
Pan Y, Chen J . MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol. 2003; 23(15):5113-21. PMC: 165735. DOI: 10.1128/MCB.23.15.5113-5121.2003. View